申请人:Kyowa Hakko Kogyo Co., Ltd.
公开号:US04396550A1
公开(公告)日:1983-08-02
Novel dibenz [b,e] oxepin derivatives represented by the general formula: ##STR1## wherein R.sub.11 represents an alkyl group containing 1 to 5 carbon atoms, an alkoxy group containing 1 to 5 carbon atoms, a halogen atom, a cyclohexyl group or a phenyl group; and R.sub.21 represents ##STR2## wherein X represents a hydrogen atom, a hydroxy group, an amino group or a substituted aralkyl group containing 7 to 20 carbon atoms, and n represents 0 or an integer of 1 to 3 ##STR3## or (3) --NH--(CH.sub.2).sub.n --Y, wherein Y represents an alkylamino group containing 1 to 5 carbon atoms, an aralkyl group containing 7 to 20 carbon atoms, a substituted aralkyl group, an aralkyloxy group containing 7 to 20 carbon atoms, an aralkylamino group containing 7 to 20 carbon atoms, a heterocyclic ring or a substituted heterocyclic ring, and n has the same meaning as defined before; provided that when R.sub.11 represents an alkyl group, an alkoxy group or a halogen atom, X does not represent a hydrogen atom; and the pharmaceutically acceptable acid addition salts thereof. Also disclosed are pharmaceutical compositions comprising a pharmaceutical carrier and, as an active ingredient, an effective amount of a dibenz [b,e] oxepin derivative represented by the following general formula: ##STR4## wherein R.sub.1 represents an alkyl group containing 1 to 5 carbon atoms, an alkoxy group containing 1 to 5 carbon atoms, a halogen atom, a cyclohexyl group or a phenyl group; and R.sub.2 represents ##STR5## wherein X represents a hydrogen atom, a hydroxy group, an amino group or a substituted aralkyl group containing 7 to 20 carbon atoms, and n has the same meaning as defined before ##STR6## or (3) --NH--(CH.sub.2).sub.n --Y, wherein Y and n have the same meaning as defined above; and the pharmaceutically acceptable acid addition salts thereof. Compound I, represented by the general formula (I), has antichlolinergic, antihistaminergic, antiasthmatic and antiplatelet aggregation activities, and is therefore useful as a sposmolysant, an antihistaminic, an antiasthmatic agent and as a medicament for cardiovascular or cerebrovascular diseases, respectively.
新型二苯并[b,e]噁喹啉衍生物由以下通式表示:其中R.sub.11代表含有1到5个碳原子的烷基基团,含有1到5个碳原子的烷氧基团,卤素原子,环己基团或苯基团;而R.sub.21表示其中X代表氢原子,羟基,氨基或含有7到20个碳原子的取代芳基基团,n表示0或1到3的整数,或(3) --NH--(CH.sub.2).sub.n --Y,其中Y代表含有1到5个碳原子的烷基氨基团,含有7到20个碳原子的取代芳基基团,取代芳基氧基团,含有7到20个碳原子的取代芳基氨基团,杂环环或取代杂环环,n具有前述定义的相同含义;但当R.sub.11代表烷基基团,烷氧基或卤素原子时,X不代表氢原子;及其药学上可接受的酸盐。还公开了包含药物载体和作为活性成分的新型二苯并[b,e]噁喹啉衍生物的药物组合物,其通式如下:其中R.sub.1代表含有1到5个碳原子的烷基基团,含有1到5个碳原子的烷氧基团,卤素原子,环己基团或苯基团;而R.sub.2表示其中X代表氢原子,羟基,氨基或含有7到20个碳原子的取代芳基基团,n具有前述定义的相同含义,或(3) --NH--(CH.sub.2).sub.n --Y,其中Y和n具有上述定义的相同含义;及其药学上可接受的酸盐。通式(I)代表的化合物I具有抗胆碱能、抗组胺能、抗哮喘和抗血小板聚集活性,因此可用作抗痉挛剂、抗组胺剂、抗哮喘剂以及心血管或脑血管疾病的药物。